Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the “Real World”—Clinical and angiographic results from the China CYPHER Select registry

Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in “Real-World” Practice

“…First, patients with device failure, which may influence the long-term prognosis, were excluded in the present study. Second, there are now several reports that suggest that the incidence of stent thrombosis is relatively low in Asian populations (30,35,36). The mechanisms of such phenomenon are unclear, but might be associated with genetic specificity.…”

The Paclitaxel‐Eluting Coroflex™ Stent Study II (PECOPS II) Acute and 6‐Month Clinical and Angiographic Follow‐Up, 1‐Year Clinical Follow‐Up

“…The patients in PECOPS II were more likely diabetic (31.3%; TAXUS II MR: 17 %; PECOPS I: 35.2%). This is important owing to the data that have associated diabetic subjects with elevated MACE rates, in particular with stent thrombosis when compared to nondiabetic patients 26–33 . In the SR arm of TAXUS II only subjects with single vessel coronary disease were included with a share of 11% diabetics.…”

“…This is important owing to the data that have associated diabetic subjects with elevated MACE rates, in particular with stent thrombosis when compared to nondiabetic patients. [26][27][28][29][30][31][32][33] In the SR arm of TAXUS II only subjects with single vessel coronary disease were included with a share of 11% diabetics. The in-segment recurrence rate was reported to be 5.5%.…”

Current status of percutaneous coronary intervention in China

“…The prospective multicentre (20-centre) China Cypher select registry (CCSR)24 enrolled 1189 consecutive patients who underwent implantation of at least one Cypher Select stent during routine interventional practice from July 2004 to November 2004. Patients who underwent emergency stenting for acute myocardial infarction (MI) were excluded.…”